ArticleJAMA cardiology2017
Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States.
Article in JAMA cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel.Annals of internal medicine · 2025Guideline
- Pooled it
- Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.The New England journal of medicine · 2023 · on this mapTrial
- Primary Cardiovascular Prevention in People Living With HIV: Rethinking Statin Therapy in the Post-REPRIEVE Era.Current HIV/AIDS reports · 2026Review
- Combining Observational Studies to Reduce Multiple Biases.Epidemiology (Cambridge, Mass.) · 2026Article
- Etiological myocardial injury classification versus binary myocardial infarction classification in the multi-ethnic study of atherosclerosis (MESA).American journal of preventive cardiology · 2026Article
- Antiviral Drugs in HIV and Cardiovascular Disease: Mechanistic Insights and Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Spectrum From Acute Myocardial Injury to Infarction Among People With Human Immunodeficiency Virus Seeking Emergency Care in the United States: Presentations, Provider Responses, and Clinical Outcomes.Open forum infectious diseases · 2025Article
- Predicting Risk of Cardiovascular Disease Events (PREVENT) score accuracy among people with HIV in the multicenter CNICS cohort.AIDS (London, England) · 2025Article
- Types of Myocardial Infarction in People With HIV in Switzerland.Open forum infectious diseases · 2025Article
- Cohort profile update: the Johns Hopkins HIV clinical cohort, 1989-2023.European journal of epidemiology · 2024Article
- HIV-Associated Hypertension: Risks, Mechanisms, and Knowledge Gaps.Circulation research · 2024Review
- Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency Virus.Open forum infectious diseases · 2023 · on this mapArticle
- Polygenic risk scores point toward potential genetic mechanisms of type 2 myocardial infarction in people with HIV.International journal of cardiology · 2023Article
- Associations between alcohol and cigarette use and type 1 and 2 myocardial infarction among people with HIV.HIV medicine · 2023Article
- Clinical Characteristics and Outcomes Among People Living With HIV Undergoing Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.Journal of the American Heart Association · 2023Article
- Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023 · on this mapArticle
- The epidemiology, mechanisms, diagnosis and treatment of cardiovascular disease in adult patients with HIV.American journal of cardiovascular disease · 2023Review
- Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study.Frontiers in medicine · 2023Article
- Investigating vascular diseases in people living with HIV by nuclear imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
29 authors at 9 institutions in 1 country.
Funding
Abstract
Importance: The Second Universal Definition of Myocardial Infarction (MI) divides MIs into different types. Type 1 MIs result spontaneously from instability of atherosclerotic plaque, whereas type 2 MIs occur in the setting of a mismatch between oxygen demand and supply, as with severe hypotension. Type 2 MIs are uncommon in the general population, but their frequency in human immunodeficiency virus (HIV)-infected individuals is unknown. Objectives: To characterize MIs, including type; identify causes of type 2 MIs; and compare demographic and clinical characteristics among HIV-infected individuals with type 1 vs type 2 MIs. Design, Setting, and Participants: This longitudinal study identified potential MIs among patients with HIV receiving clinical care at 6 US sites from January 1, 1996, to March 1, 2014, using diagnoses and cardiac biomarkers recorded in the centralized data repository. Sites assembled deidentified packets, including physician notes and electrocardiograms, procedures, and clinical laboratory tests. Two physician experts adjudicated each event, categorizing each definite or probable MI as type 1 or type 2 and identifying the causes of type 2 MI. Main Outcomes and Measures: The number and proportion of type 1 vs type 2 MIs, demographic and clinical characteristics among those with type 1 vs type 2 MIs, and the causes of type 2 MIs. Results: Among 571 patients (median age, 49 years [interquartile range, 43-55 years]; 430 men and 141 women) with definite or probable MIs, 288 MIs (50.4%) were type 2 and 283 (49.6%) were type 1. In analyses of type 1 MIs, 79 patients who underwent cardiac interventions, such as coronary artery bypass graft surgery, were also included, totaling 362 patients. Sepsis or bacteremia (100 [34.7%]) and recent use of cocaine or other illicit drugs (39 [13.5%]) were the most common causes of type 2 MIs. A higher proportion of patients with type 2 MIs were younger than 40 years (47 of 288 [16.3%] vs 32 of 362 [8.8%]) and had lower current CD4 cell counts (median, 230 vs 383 cells/µL), lipid levels (mean [SD] total cholesterol level, 167 [63] vs 190 [54] mg/dL, and mean (SD) Framingham risk scores (8% [7%] vs 10% [8%]) than those with type 1 MIs or who underwent cardiac interventions. Conclusions and Relevance: Approximately half of all MIs among HIV-infected individuals were type 2 MIs caused by heterogeneous clinical conditions, including sepsis or bacteremia and recent use of cocaine or other illicit drugs. Demographic characteristics and cardiovascular risk factors among those with type 1 and type 2 MIs differed, suggesting the need to specifically consider type among HIV-infected individuals to further understand MI outcomes and to guide prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.